Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation

Acta Neuropathol. 2024 Oct 30;148(1):58. doi: 10.1007/s00401-024-02816-9.

Abstract

Synaptic dysfunction and loss are central to neurodegenerative diseases and correlate with cognitive decline. Synaptic Vesicle Protein 2A (SV2A) is a promising PET-imaging target for assessing synaptic density in vivo, but comprehensive mapping in the human brain is needed to validate its biomarker potential. This study used quantitative immunohistochemistry and Western blotting to map SV2A and synaptophysin (SYP) densities across six cortical regions in healthy controls and patients with early-onset Alzheimer's disease (EOAD), late-onset Alzheimer's disease (LOAD), progressive supranuclear palsy (PSP), and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-GRN). We identified region in SV2A density among controls and observed disease- and region-specific reductions, with the most severe in FTLD-GRN (up to 59.5%) and EOAD. EOAD showed a 49% reduction in the middle frontal gyrus (MFG), while LOAD had over 30% declines in the inferior frontal gyrus (IFG) and hippocampus (CA1). In PSP, smaller but significant reductions were noted in the hippocampal formation, with the inferior temporal gyrus (ITG) relatively unaffected. A strong positive correlation between SV2A and SYP densities confirmed SV2A's reliability as a synaptic integrity marker. This study supports the use of SV2A PET imaging for early diagnosis and monitoring of neurodegenerative diseases, providing essential data for interpreting in vivo PET results. Further research should explore SV2A as a therapeutic target and validate these findings in larger, longitudinal studies.

Keywords: Alzheimer’s disease; Frontotemporal lobar degeneration; Postmortem; Progressive supranuclear palsy; SV2A; Synaptophysin.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease* / diagnostic imaging
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Brain / pathology
  • Female
  • Frontotemporal Lobar Degeneration / diagnostic imaging
  • Frontotemporal Lobar Degeneration / metabolism
  • Frontotemporal Lobar Degeneration / pathology
  • Humans
  • Male
  • Membrane Glycoproteins* / metabolism
  • Middle Aged
  • Nerve Tissue Proteins* / metabolism
  • Neurodegenerative Diseases / diagnostic imaging
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology
  • Positron-Emission Tomography* / methods
  • Supranuclear Palsy, Progressive / diagnostic imaging
  • Supranuclear Palsy, Progressive / metabolism
  • Supranuclear Palsy, Progressive / pathology
  • Synaptophysin* / metabolism

Substances

  • Synaptophysin
  • SV2A protein, human
  • Membrane Glycoproteins
  • Nerve Tissue Proteins
  • SYP protein, human